Y-mabs announces partnership regarding early access program for danyelza (naxitamab-gqgk) in europe

New york, dec. 21, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with wep clinical ltd. (“wep”) in connection with an early access program for danyelza (naxitamab-gqgk) 40mg/10ml injection in europe.
YMAB Ratings Summary
YMAB Quant Ranking